Indeed, Takeda and colleagues used a cancer vaccine, containing a tumor-associated antigen (TAA) to ARNAX, for the treatment of murine T cell lymphoma by subcutaneous injection, thus inducing CD8+ T cell priming through activation of the TLR3-TICAM-1-IRF3-IFN-β pathway in DCs. The gene discussed is TLR3; the disease is cancer.